Increasing cure rates of solid tumors by immune checkpoint inhibitors.

Autor: Ma W; Chinese American Hematologist and Oncologist Network, New York, NY, USA.; Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03756, USA., Xue R; Chinese American Hematologist and Oncologist Network, New York, NY, USA.; Ellis Fischel Cancer Center, University of Missouri, 1 Hospital Dr, Columbia, MO, 65201, USA., Zhu Z; Chinese American Hematologist and Oncologist Network, New York, NY, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Farrukh H; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Song W; Chinese American Hematologist and Oncologist Network, New York, NY, USA.; Kira Pharmaceuticals, Cambridge, MA, USA., Li T; Chinese American Hematologist and Oncologist Network, New York, NY, USA. thli@ucdavis.edu.; Department of Medicine, Division of Hematology & Oncology, University of California Davis, Sacramento, CA, 95817, USA. thli@ucdavis.edu.; Department of Medicine, VA Northern California Health Care System, Mather, CA, USA. thli@ucdavis.edu., Zheng L; Chinese American Hematologist and Oncologist Network, New York, NY, USA. lzheng6@jhmi.edu.; The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. lzheng6@jhmi.edu., Pan CX; Chinese American Hematologist and Oncologist Network, New York, NY, USA. Chongxian_pan@hms.harvard.edu.; VA Boston Healthcare System, Boston, MA, 02132, USA. Chongxian_pan@hms.harvard.edu.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Chongxian_pan@hms.harvard.edu.
Jazyk: angličtina
Zdroj: Experimental hematology & oncology [Exp Hematol Oncol] 2023 Jan 16; Vol. 12 (1), pp. 10. Date of Electronic Publication: 2023 Jan 16.
DOI: 10.1186/s40164-023-00372-8
Abstrakt: Immunotherapy has become the central pillar of cancer therapy. Immune checkpoint inhibitors (ICIs), a major category of tumor immunotherapy, reactivate preexisting anticancer immunity. Initially, ICIs were approved only for advanced and metastatic cancers in the salvage setting after or concurrent with chemotherapy at a response rate of around 20-30% with a few exceptions. With significant progress over the decade, advances in immunotherapy have led to numerous clinical trials investigating ICIs as neoadjuvant and/or adjuvant therapies for resectable solid tumors. The promising results of these trials have led to the United States Food and Drug Administration (FDA) approvals of ICIs as neoadjuvant or adjuvant therapies for non-small cell lung cancer, melanoma, triple-negative breast cancer, and bladder cancer, and the list continues to grow. This therapy represents a paradigm shift in cancer treatment, as many early-stage cancer patients could be cured with the introduction of immunotherapy in the early stages of cancer. Therefore, this topic became one of the main themes at the 2021 China Cancer Immunotherapy Workshop co-organized by the Chinese American Hematologist and Oncologist Network, the China National Medical Products Administration and the Tsinghua University School of Medicine. This review article summarizes the current landscape of ICI-based immunotherapy, emphasizing the new clinical developments of ICIs as curative neoadjuvant and adjuvant therapies for early-stage disease.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje